1032350-05-2

Basic information

• Product Name: 1-(4-bromophenyl)cyclobutane-1-carboxamide
• Synonyms: 1-(4-bromophenyl)cyclobutane-1-carboxamide;1-(4-bromophenyl)cyclobutanecarboxamide
• CAS NO: 1032350-05-2
• Molecular Formula: C₁₁H₁₂BrNO
• Molecular Weight: 254.12308
• EINECS: -0
• Mol File: 1032350-05-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-bromophenyl)cyclobutane-1-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-bromophenyl)cyclobutane-1-carboxamide(1032350-05-2)
• EPA Substance Registry System: 1-(4-bromophenyl)cyclobutane-1-carboxamide(1032350-05-2)

Safety Data

• Hazardous Substances Data: 1032350-05-2(Hazardous Substances Data)

Usage

General Description

1-(4-bromophenyl)cyclobutane-1-carboxamide is a chemical compound with the molecular formula C11H12BrNO. It is a cyclobutane derivative that contains a bromophenyl group and a carboxamide functional group. 1-(4-bromophenyl)cyclobutane-1-carboxamide is typically used in pharmaceutical research and drug development, where it may be investigated for its potential therapeutic properties. As a cyclobutane derivative, it may exhibit unique structural and chemical properties that could make it useful in various applications. However, further research and testing would be necessary to fully understand its potential uses and properties.

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 485828-58-8 1-(4- bromophenyl)cyclobutane-1-carbonitrile 

Downstream Products

• 1032350-06-3 tert-butyl (1-(4-bromophenyl)cyclobutyl)carbamate 
• 1467059-20-6 5-(4-(1-carbamoylcyclobutyl)phenyl)-6-chloro-1H-indazole-3-carboxylic acid 
• 1193389-40-0 1-(4-bromophenyl)cyclobutane-1-amine hydrochloride 
• 1313881-70-7 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine 
• 1313881-69-4 tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)cyclobutyl)carbamate 
• 1439394-28-1 tert-butyl (1-(4-((3-nitro-6-phenylpyridin-2-yl)amino)phenyl)cyclobutyl)carbamate 
• 1439394-30-5 tert-butyl(1-(4-((3-amino-6-phenylpyridin-2-yl)amino)phenyl)cyclobutyl)carbamate 
• 1094218-30-0 1-(4-bromophenyl)cyclobutanamine 

Relevant articles and documents

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

IL-23 ANTAGONISTS FOR TREATMENT OR PREVENTION OF SKIN RASH ASSOCIATED WITH TREATMENT WITH P13K/AKT PATHWAY INHIBITORS

The present invention provides methods for use of interleukin-23 (IL-23) antagonists to treat or prevent skin rash associated with treatment with PI3K/AKT pathway inhibitors, such as treatment of cancer.

Inhibitors of Akt activity

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.